Essential Hypertension in Children: New Mechanistic Insights by Samuelsson, Anne-Maj Sofia
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 2
Essential Hypertension in Children: New Mechanistic
Insights
Anne-Maj Sofia Samuelsson
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/62652
Abstract
Paediatric  hypertension  is  on  the  rise  accompanied  by  concomitant  increase  of
childhood obesity. The origin of paediatric hypertension however remains unknown.
New epidemiological evidence suggests that environmental insult in utero or postna‐
tally may lead to hypertension later in life. Independent associations have been reported
between maternal obesity and cardiometabolic disorders in the offspring. In the first
part, I will focus on functionally mechanistic pathways of essential hypertension with
an attempt to elucidate the rather complex interplay of autonomic dysfunction, leptin,
melanocortin-4  receptor  (MC4R),  inflammation,  genetic  and epigenetic  predisposi‐
tions. In the second part, the standalone risk factors will be integrated in a flow chart in
attempt to understand the deeper meaning of this regulatory machinery in paediatric
hypertension.  I  will  refer  to  the  pathophysiology  of  early  sympathetic-mediated
hypertension arising from maternal obesity. Maternal diet-induced obesity in rodents
permanently resets the responsiveness to leptin-induced SNS in rat offspring via the
hypothalamic  paraventricular  nucleus  (PVN)-MC4R  pathway.  The  stimulus  that
mediates Leptin-SNS-MC4R activity and promotes hypertension is still unknown and
remains as a key for future investigations. Future research needs to identify effective
preventive measures in the pregnant mother and child to reduce the risk of paediatric
hypertension and prevent future cardiovascular disease.
Keywords: essential hypertension, maternal obesity, leptin, melanocortin system,
sympathetic activity, hypothalamus
1. Introduction
Hypertension in children and adolescence is becoming an increasing health problem. The
prevalence of pre-hypertension is approximately 14% in boys and 6% in girls (age 8–17 years)
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[1, 2], and the prevalence of hypertension is estimated to be 3–4% (age 3–18 years) [3, 4]. One in
three of the hypertensive children develops end-organ damage, including ventricular hyper‐
trophy [5], chronic kidney disease [6] and vascular changes [7] and cognitive impairment [8, 9],
all predictors for premature morbidity and mortality. Accumulating evidence supports the
theory that elevated blood pressure levels in adolescence are a precursor of elevated blood
pressure in adulthood, and an important risk factor for future cardiovascular diseases [10].
Another factor is the coexistent epidemic of childhood obesity, which in the US rose from 5 to
11% from the 1960s to the 1990 [11, 12], becoming a concomitant cardiovascular risk factor.
Childhood BMI has strong positive concordance with blood pressure [13]. Children who are
overweight demonstrate 4.5 and 2.3 times higher risk of developing increased systolic blood
pressure and diastolic blood pressure, respectively [14], consistent findings were obtained by
Sorof et al. [15] with a three-fold prevalence of childhood hypertension in obese versus lean at
school age. Blood pressure in children may also vary by age, sex, race and height [4] but not as
solid as BMI, all these inclusion criteria of risk being underdiagnosed [3]. Children within the
“normotensive” range of blood pressure demonstrate elevated left ventricular mass [16] and
greater risk of developing hypertension in adulthood [17]. Thus, blood pressure in children
diverges from adults in that an underestimation of risk may cause severe cardiovascular diseases
in adulthood [18].  Recent report  indicates that  more than 90% of children evaluated for
hypertension have no underlying cause identified [19], which suggests that prevalence of
essential hypertension is increasing. This revives the discussion of the aetiology and pathogen‐
esis research of essential hypertension to identify important targets of prevention.
2. Pathophysiology of childhood hypertension
The origin of paediatric hypertension evolves a cluster of metabolic and haemodynamic
disorders identifies as a polyfactorial disease. Unfavourable metabolic profiles, such as
hyperinsulineaemia and dyslipidaemia, at an young age with abnormalities of vascular
structure and function leads to adverse cardiovascular outcome [12, 20, 21]. The adverse
metabolic profile may originate from an unbalanced autonomic nervous system (ANS). ANS
is known as the major adaptor for stress responses which regulate the two neural efferent
pathways the parasympathetic and sympathetic system [22]. Long-term increase to stress
may lead to increased sympathetic activity and decreased parasympathetic activity, contri‐
buting to obesity, insulin resistance, dyslipidaemia and hypertension [23–25]. Dysregula‐
tion of ANS may therefore predict metabolic abnormalities [26, 27] and hypertension [22]. In
children, these associations have barely been investigated. Childhood obesity has been
associated with lower parasympathetic activity [28–31], but more conflicting results regard‐
ing the influence of the sympathovagal balance and sympathetic hyperactivity [31–33].
Possible confounding factors and differences in methodology and sample size might explain
these differences. Latchman et al. [32] showed that normotensive obese 9-year-old children
exhibited reduced baroreflex sensitivity, parasympathetic control as well as increased
sympathetic control compared with normotensive lean children. Thus, suggest that auto‐
nomic dysfunction may precede the hypertension in obese children. Obesity is associated
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with increased sympathetic nervous system (SNS) activity, with impaired heart rate varia‐
bility [34]. The resting heart rate is positively correlated with sub-capsular skinfold thick‐
ness in children [35]. Similar findings have been obtained in early origin of cardiometabolic
disease. Foetuses born to obese mothers demonstrate increased foetal sympathetic activa‐
tion [36], which may predict long-term cardiovascular outcome.
3. Maternal obesity and offspring cardiovascular complications
A large body of epidemiological literature supports the link between an adverse intrauterine
environment and disease in later life, showing inverse association between low birth weights
(poor nutrition) with subsequent hypertension [37–40]. Similar findings have been demon‐
strated in animal models of maternal malnutrition and uterine growth restriction (IUGR) [41].
Despite the worldwide obesity epidemic, relative few studies have investigated the influence
of maternal obesity on offspring health, with only recent emerging human data suggesting
detrimental effects with preterm mortality in the offspring [42]. Epidemiological study
demonstrates associations between maternal BMI and increased systolic blood pressure (SBP)
in 7-year-old children [43]. The Amsterdam Born Children and their Development (ABCD)
study recently reported that maternal pre-pregnancy BMI, in 3074 women, was positively
associated with childhood diastolic blood pressure (DBP) and SBP at the age of 5–6 [44]. In the
Jerusalem perinatal study (JPS), both gestational weight gain (GWG) and pre-pregnancy BMI
were related to cardiovascular risk factors including SBP and DBP in adult offspring, at the
age of 32 [45]. A stronger association for maternal pre-pregnancy BMI than paternal BMI with
adverse cardiometabolic health in offspring suggests a direct intrauterine mechanisms, instead
of life-style-related characteristics or genetic factors [46]. However, the causation is difficult to
establish in human cohort studies. Interestingly, a recent study demonstrated an increased risk
for cardiovascular mortality in children born to obese mothers, and this association remained
after removing the child BMI [42]. Thus, suggests a direct effect of maternal obesity on child
cardiovascular function, independent of childhood obesity [42]. The WHO Global Burden of
Disease database currently identifies a rapid rise in maternal obesity in the past two decades.
In the US, 64% of women of reproductive age are overweight and 35% are obese [47], with a
similar pattern in Europe [48] and the rest of the world [49–51]. Obese pregnant women not
only develop a higher risk of preeclampsia, preterm labour, stillbirth, caesarean deliveries,
there are also a higher incidence of developing diabetes and hypertension in the offspring [52].
The increasing rate of maternal obesity may therefore provide a major challenge to future
generations’ health. Children born to obese mothers not only are prone to develop obesity but
also essential hypertension which is the primary risk factor for developing other cardiovas‐
cular diseases leading to premature death. Whilst further randomised controlled clinical trials
of improved design are indicated, there is an important task to revisit the basic science of
autonomic function using experimental models that mimics the human condition of essential
hypertension.
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3.1. Autonomic dysfunction and paediatric hypertension
The autonomic nervous system (ANS) has two principal divisions, the parasympathetic
pathway and the sympathetic pathway which acts either in synergy or in opposition synergy.
The autonomic system continuously controls heart rate and blood pressure, respiratory rate
and gut motility, body temperature and other essential functions. The autonomic function
interacts with the primitive brain, including the limbic system (memory function), brain stem
and hypothalamus [53]. Neurons within hypothalamic nuclei, particularly the paraventricular
nucleus (PVN) and dorsomedial hypothalamus (DMN), make direct or indirect connection
with sympathetic and parasympathetic preganglionic neurons and interfere with autonomic
balance, sympathetic hyperactivity and neurogenic hypertension [53]. Early stages of hyper‐
tension, particularly in children, are defined by autonomic dysfunction [54]. Excessive
sympathetic activity and/or withdrawal of parasympathetic balance are assessed by HR
variability (HRV), using the ratio of low to high frequency (LF/HF) power. Pioneering studies
conducted by Urbina et al. showed altered HRV in 39 male adolescences and reported trends
of higher LF/HF ratio with higher BP, but did not reach statistical significance [65]. In a larger
cohort, Sorof et al. [20] reported increased HR and BP variability in obese children with isolated
systolic hypertension assessed by office HR/BP measurement and ambulatory blood pressure
monitoring (ABPM). Interestingly, obese hypertensive children had higher HR than non-obese
hypertensive children, suggesting that obesity is independently related with SNS activation
[20]. These initial findings of SNS hyperactivity in hypertensive children, measured by indirect
methods, were later confirmed by direct measurement of sympathetic activity using micro‐
neurography [55]. Zhou et al. [56] demonstrated altered vagal and sympathetic activity in
hypertensive children, with a greater influence of systolic blood pressure (SBP) than diastolic
blood pressure (DBP) on HRV [57]. Genovesi et al. [58] demonstrated baroreflex impairment,
in both hypertensive and pre-hypertensive children. Autonomic dysfunction is therefore
considered a critical feature in pre-hypertensive children which may predict future cardio‐
vascular health. In children with arterial hypertension, the increase of sympathetic activity
during sleep correlate with increase left ventricular mass and left ventricular mass index [59].
Moreover, HRV can predict the severity of children with pulmonary arterial hypertension [60].
This is particular worrisome as historical reference data on child HRV by Massin et al. [61]
with current child HRV in Germany [62] showed change in children’s ANS in the last 15 years.
These changes constitute reduced vagal activity and a shift towards sympathetic dominance
[62]. The authors suggest that these changes might be related to the rise in childhood obesity,
with a negative association between BMI and ANS activity [62]. The historical samples of
Kauzuma et al. [63], however, featured a comparable overweight rate (17%), but still reported
much lower mean sympathetic activity. Additional factors including physical inactivity or
nutrient composition may influence ANS [64, 65]. Maternal BMI, which recently been associ‐
ated with the offspring ANS activity, may be another important determinant [66]. Several
different mechanisms leading to and maintaining central sympathetic hyperactivity in
essential hypertension have been identified. An impaired vagal heart rate control exerted by
arterial baroreflex impaired volume-sensitive cardiopulmonary reflex, arterial chemorecep‐
tors as well as humoral factors such as leptin and angiotensin II with direct central sympa‐
thoexcitatory effects have all been shown to play at least partial roles in essential hypertension.
Update on Essential Hypertension12
3.2. Leptin and childhood obesity and hypertension
Experimental models of maternal obesity in sheep, non-human primate and rodents provide
evidence for the adverse influence on offspring cardiovascular function [67]. In rodents, the
perinatal exposure to metabolic milieu of maternal obesity may permanently change the
central pathways involved in blood pressure regulation [66]. Leptin, an adipocyte-derived
hormone, promotes weight loss by reducing appetite and increasing energy expenditure
through hypothalamic sympathetic stimulation to brown adipose tissue [68] and kidney [69]
which results in increased arterial pressure [70]. This has been confirmed in chronic infusion
of leptin in rats developing increased blood pressure [71]. Transgenic mice overexpressing
leptin develops overt obesity with elevations of blood pressure [72]. Selective leptin resistance
of the appetite and weight reducing effect of leptin [73], and preservation of the sympathetic
action of leptin, been implicated in obesity-related hypertension [74]. In humans, high plasma
leptin concentration has been associated with arterial pressure [75] and muscle sympathetic
nerve activity [76]. Leptin is also thought to have a neurotrophic role in the development of
the hypothalamus [77], and altered neonatal leptin profiles secondary to maternal obesity are
associated with permanently altered brain hypothalamic structure and function. In rodent
studies, maternal obesity confers persistent sympathoexcitatory hyper-responsiveness and
hypertension acquired in the early stages of development [78]. Unrevealing the mechanisms
controlling hypothalamic development may help to identify the nature of the hypothalamic
dysfunction and develop future therapies. High leptin in cord blood from foetuses of obese
mothers [79] might cause permanent changes of the hypothalamic circuits leading to height‐
ened leptin-induced sympathetic activity and blood pressure in juvenile offspring, prior to
obesity and metabolic dysfunction [70].
3.3. The role of the central melanocortin system
The melanocortin system is an essential pathway in central regulation of metabolic and
cardiovascular function. Central pro-opiomelanocortin (POMC) containing neurons in the
arcuate nucleus (ARC) of the hypothalamus and the brain stem (e.g. nucleus of the tractus
solitaries, NTS) project to other brain regions involved in energy homeostasis but also
cardiovascular regulation [80]. The POMC neurons stimulate melanocortin receptor sub‐
type 3 (MC3R) and 4 (MC4R) and reduce appetite and increase energy expenditure, SNS
activity and BP [80]. Mutation of the melanocortin-4 receptor (MC4R) or pro-opiomelanocor‐
tin (POMC) gene estimates for 5–6% of early onset obesity in human [81]. Pharmacological
blockade of MC4R causes pronounced obesity in rodents [82], whereas activation of MC4R
promotes weight loss by reducing appetite and increase energy expenditure [83, 84]. Con‐
versely, chronic MC4R activation causes sustained increased in BP despite reducing food
intake and promoting weight loss [85]. MC4R-deficient rodents demonstrate reduced SNS
activity and BP, independent of obesity [86]. Similar observations have been shown in
humans, and MC4R deficiency leads to obesity but exhibits lower BP and reduced 24-h
noradrenaline excretion compared with obese subjects with normal MC4R function [87, 88].
We and others have also demonstrated a critical role for the POMC-neurons MC4R axis in
mediating appetite-suppressing and blood pressure effects of leptin [89, 90]. Rahmouni et al.
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[89] showed that acute effect of leptin-induced hypophagia and renal SNS activity which were
attenuated and abolished in heterozygous and homozygous MC4R knockout mice, respec‐
tively. Intact POMC neurons-MC4R axis is also required in chronic leptin-induced SNS
activity and BP regulation [91]. MC4R antagonism markedly reduced BP in juvenile off‐
spring born to obese dams (OffOb) [90] and spontaneous hypertensive rats (SHR) [92] two
experimental models of hypertension that is associated with increased SNS activity in the
absence of obesity [70, 93]. MC4R antagonism also attenuates or abolishes the acute pressor
responses to leptin that raises BP by SNS stimulation [92]. Collectively, these observations
suggest that the MC4R plays a key role in contributing to elevated BP in several forms of
hypertension that accompany SNS overactivity. Greatest abundance of MC4R is the paraven‐
tricular nucleus of the hypothalamus (PVN), lateral hypothalamus (LH), the amygdala, the
NTS and the preganglionic sympathetic neurons, which are all important sites for regula‐
tion of autonomic function [80]. Although the specific contribution of MC4R in distinct CNS
nuclei in mediating the actions of the brain melanocortin system on energy balance, appe‐
tite and glucose homeostasis has been the subject of intense investigation, the particular
regions of the brain, where MC4R is the most important in regulation of SNS activity and BP,
are still unclear. We have recently shown that the activation of MC4R in the PVN (using sim-
cre genetic-modified mice) demonstrated increased BP in offspring of obese dams that were
protected in the MC4R-mutated mice; suggest an important role for MC4R in PVN in
contributing to early onset hypertension [90]. One study has also observed that specific
neuronal populations including cholinergic preganglionic parasympathetic and sympathet‐
ic neurons are involved in MC4R-mediated hypertension [94]. The specific stimuli that
mediate the effect of MC4R to evoke sustained increases in SNS activity to cardiovascular-
relevant tissue and promote chronic increase in BP are still unknown and remain an impor‐
tant area for future investigations.
3.4. Common genetic traits in paediatric hypertension
There has been a great progress in elucidating molecular targets for hypertension from
monogenic disorders [95]. Among the most significant findings has been from single-gene
disorders with primary effect on blood pressure that acts via common pathway alterations
including renin-angiotensin and melanocortin system [95]. Recent genome-wide association
studies (GWASs), conducted mostly in Europeans, have identified >30 genomic loci associated
with systolic/diastolic BP [96], including candidate genes angiotensinogen [97], angiotensin-
converting enzyme (ACE) [98], and alpha 2 adrenergic receptor genes (ADRA2A) [98]. The
GWAS analysis is, however, inconsistent between populations, with a great gene-environment
interaction, that significantly contributes to the increased risk of hypertension [99]. Obesity is
one of the most dominant risk factor of childhood hypertension with a common genetic traits
in FTO [100] and downstream of MC4R [101]. Hypertension has been associated with the risk
allele A for FTO rs9939609 and the risk allele C for MC4R rs17782313, independent of BMI [102,
103]. Recent study by Sun et al. demonstrated an association of the FTO rs9939609 and MC4R
rs17782313 genes with nocturnal blood pressure in the Chinese Han population [104]. The
effect sizes are, however, small for each individual genetic variant, typically 1 mmHg for SBP
and 0.5 mmHg for DBP [105]. Even collectively, the 30 variants tested in one experiment explain
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only 1–2% of SBP and DBP variance [105]. Heritability of hypertension is estimated to be
between 30 and 40% which is approximately 25 times larger than the phenotypic variation and
disease risk currently explained by GWAS SNPs. The observation that only little of the total
heritability can be currently be explained by the GWAS has led to the term “missing herita‐
bility” [106]. It is expected that many more yet undiscovered loci, possible including variants
in the rare allele spectrum that might have larger effects sizes, will contribute to explain the
missing heritability [106]. It has been suggested that epigenetic changes may account for the
missing heritability determinants of complex diseases, such as hypertension.
3.5. Epigenetic traits in experimental model of hypertension
Recent years have shown a dramatic interest in the epigenetic trait of human disease. Pheno‐
typic variation is regulated independent of changes in DNA sequence, such as DNA methyl‐
ation, histone modification, chromatin remodelling and the action of small noncoding RNAs
(microRNA) [107]. These epigenetic modifications change the accessibility of gene promoter
sequence (by methyl donor) and binding domain [107]. Several animal studies have charac‐
terise epigenetic modification influenced by the intrauterine environment (maternal stress,
nutrition and behaviour) [107]. In cardiovascular disease, recent studies of low-protein diet
during pregnancy showed early onset hypertension in the offspring [108]. The renin-angio‐
tensin system showed to be a main target as angiotensin receptor (AT1R) antagonist reversed
the hypertension in the offspring [108]. Consistent with these finding, offspring showed a
hypomethylated AT1R gene promoter along with the increased expression of AT1R [109],
suggesting a role for specific AT1R hypomethylation in regulating elevated blood pressure in
this model. Similar epigenetic modification has been shown in the hypothalamic POMC
neurons in a rat model of neonatal overfeeding [110]. Hypothalamic POMC showed hyper‐
methylated in the overfed neonates and consequently influence the set point of the melano‐
cortin system which is critical for metabolic and cardiovascular regulation [110]. Fewer studies
of epigenetic changes have been conducted in primates, and there is little direct evidence
relating this to humans. One study showed a correlation of epigenetic RXRA (retinoid X
receptor alpha—induces transcription of PPARs) promoter methylation with increased
adiposity in children of mothers with lower carbohydrate intake in two independent cohorts
[111]. Although this fails to confirm a causal relationship, it may provide an objective marker
in identifying children at risk of obesity and hypertension-induced cardiac hypertrophy [112].
3.6. The role of central inflammation
Several reports have demonstrated enhanced inflammatory profile with paediatric hyperten‐
sion [113, 114]. The C-reactive protein (CRP) which normally is involved in innate immune
responses is heightened both in hypertensive and pre-hypertensive obese children, suggesting
that systemic low-grade inflammation may precede hypertension [115]. This has been further
confirmed in animal models of hypertension. Spontaneous hypertensive rats (SHR) a genetic
model of essential hypertension demonstrate increased renal infiltration of lymphocytes and
macrophages and activation of nuclear factor –kappa B (NF-kB) in 3-week-old pre-hyperten‐
sive rats [116]. Serum CRP has also been associated with cardiovascular risk factors in children
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including BP variability [117], intima media thickness [118], arterial stiffness [119], left
ventricular hypertrophy [120]. Obese children and adolescence also demonstrate elevated
serum concentration of pro-inflammatory cytokines interleukin-6 (IL-6) IL-1β and ICAM-1
(intercellular cell adhesion molecule-1) with increased ambulatory BP [121]. The pro-inflam‐
matory cytokines may also be increased due to obesity alone, independent of essential
hypertension [122]. However, the highest concentration of these molecules was found in
children with co-existing hypertension [114]. Mounting evidence suggests that the pro-
inflammatory condition in mother may induce inflammation-induced hypertension in their
offspring [123]. An overactive immune response during pregnancy, as shown in obese
pregnancy [124], can lead to chronic neuro-inflammation in the foetus [125]. Activated
microglia, resident immune cells in the brain, increases pro-inflammatory cytokines release
from the PVN, which stimulate preganglionic nerve fibres and sympathetic nerve activity
(SNA) [126]. Vice versa, SNA has a direct impact on microglia via adrenergic receptors [127]
or indirect via regulating distribution and production of lymphocytes, or modulating the
release of pro-inflammatory peptides. SNA is also involved in inflammatory cell recruitment
and redistribution, and SNA mobilise inflammatory cells from spleen and bone marrow [128].
In addition, parasympathetic nervous system has anti-inflammatory effects [129]. Vagal
afferents sense peripheral inflammation and feedback via the cholinergic anti-inflammatory
pathway [129]. There are also important direct effects of cytokines and angiotensin II on the
brain that certainly could contribute to SNA [129, 130]. Catheter-base renal denervation is a
promising therapeutic approach to treat hypertension [131], and recent animal studies suggest
Figure 1. Mechanistic overview of the developmental origin of hypertension.
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an improvement of renal inflammation with reduced renal macrophages and levels of cortical
TNF-alpha and suggest a potential target for renal injury and dysfunction [132]. Minocyclin
treatment, an anti-inflammatory antibiotic that crosses the blood brain barrier, has shown to
prevent autonomic dysfunction and hypertension in experimental models of hypertension
[126]. The reduction in blood pressure was associated with “de-activation” of the microglia in
the PVN [126]. Overall, all these studies suggest a potentially important link between inflam‐
mation, melanocortin system, developing brain and autonomic dysfunction in the environ‐
mental and genetic predisposition of hypertension arising from maternal diet-induced obesity
(Figure 1).
4. Future research and intervention strategies
Paediatric hypertension has been gaining significant attention in the last decade, mainly due
to the increased prevalence worldwide. The estimated prevalence of paediatric hypertension
is from 1 to 10%, with a steady rise over time. Alarming rate of childhood obesity and metabolic
syndrome with the precondition of maternal obesity may worsen the future cardiovascular
morbidity and mortality. This could be hypothetically prevented by early diagnosis and
management in children before they even develop the pathophysiological progression state of
hypertension. In fact, certain drugs may fail to reduce sympathetic hyperactivity as other
stimuli of SNA have become predominant in elevating SNA, which are independent of the
standard antihypertensive strategies. The progress and impact of preventive blood pressure
screening for children could also inhibit adult hypertension and cardiovascular disease.
Therefore, increased alertness to paediatric hypertension including several risk parameters
(genetic, maternal, inflammatory, adiposity) and standardise sequential ABPM monitoring to
avoid “white-coat” and “masked” hypertension in the diagnosis could improve future
statistics in adverse cardiovascular outcome. Research effort should continue with the goal to
clarify the aetiology, complexity and inheritable factors of paediatric hypertension. Research
efforts should also focus on optimal treatment of these children and on effective preventive
measures starting in the pregnant mother to the child at a young age.
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